Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Keneuoe Cecilia Nthontho, Andrew Khulekani Ndlovu, Kirthana Sharma, Ishmael Kasvosve, Daniel Louis Hertz & Giacomo Maria Paganotti. (2022) Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. Pharmacogenomics and Personalized Medicine 15, pages 613-652.
Read now
Read now
X. Ruan, A. O. Mueck, A.-M. Beer, B. Naser & S. Pickartz. (2019) Benefit–risk profile of black cohosh (isopropanolic Cimicifuga racemosa extract) with and without St John’s wort in breast cancer patients. Climacteric 22:4, pages 339-347.
Read now
Read now
Xiaoman Liu, Siew-Kee Low & Alan V. Boddy. (2016) The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors. Expert Opinion on Drug Metabolism & Toxicology 12:8, pages 851-863.
Read now
Read now
Pilar H Saladores, Jana C Precht, Werner Schroth, Hiltrud Brauch & Matthias Schwab. (2013) Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. Expert Review of Molecular Diagnostics 13:4, pages 349-365.
Read now
Read now
Jing Song, Yan Zhan, Xiaoyan Chen, Yifan Zhang & Dafang Zhong. (2013) QUANTIFICATION OF LETROZOLE IN HUMAN PLASMA USING LC-(–)ESI-MS/MS WITH D4-LETROZOLE AS INTERNAL STANDARD: APPLICATION IN A PHARMACOKINETIC STUDY. Journal of Liquid Chromatography & Related Technologies 36:13, pages 1762-1776.
Read now
Read now
Abdullah Turkistani & Sharon Marsh. (2012) Pharmacogenomics of third-generation aromatase inhibitors. Expert Opinion on Pharmacotherapy 13:9, pages 1299-1307.
Read now
Read now
Articles from other publishers (37)
SHERRY‐ANN BROWN, CRAIG BEAVERS, SAILAJA KAMARAJU, MEERA MOHAN, OLUBADEWA FATUNDE, GIFT ECHEFU, SVETLANA ZAHAROVA, BRIANNA WALLACE & CAROLYN OXENCIS. 2022. Drug Metabolism Handbook. Drug Metabolism Handbook
967
992
.
Meghan J. Chenoweth, Lisa Sanderson Cox, Nikki L. Nollen, Jasjit S. Ahluwalia, Neal L. Benowitz, Caryn Lerman, Jo Knight & Rachel F. Tyndale. (2021) Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. Scientific Reports 11:1.
Crossref
Crossref
Sailaja KamarajuMeera MohanSvetlana ZaharovaBrianna WallaceJoseph McGrawJames LokkenJohn TierneyElizabeth WeilOlubadewa FatundeSherry-Ann Brown. (2021) Interactions between cardiology and oncology drugs in precision cardio-oncology. Clinical Science 135:11, pages 1333-1351.
Crossref
Crossref
Jadwiga Buchwald, Meghan J. Chenoweth, Teemu Palviainen, Gu Zhu, Christian Benner, Scott Gordon, Tellervo Korhonen, Samuli Ripatti, Pamela A. F. Madden, Terho Lehtimäki, Olli T. Raitakari, Veikko Salomaa, Richard J. Rose, Tony P. George, Caryn Lerman, Matti Pirinen, Nicholas G. Martin, Jaakko Kaprio, Anu Loukola & Rachel F. Tyndale. (2020) Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. Molecular Psychiatry 26:6, pages 2212-2223.
Crossref
Crossref
Priyanka Arora, Gary Gudelsky & Pankaj B. Desai. (2021) Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights. PLOS ONE 16:4, pages e0248579.
Crossref
Crossref
Beatriz Carvalho Henriques, Esther H. Yang, Diego Lapetina, Michael S. Carr, Vasyl Yavorskyy, Joshua Hague & Katherine J. Aitchison. (2020) How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. Frontiers in Genetics 11.
Crossref
Crossref
Michael J. Espiritu, Justin Chen, Jaydeep Yadav, Michael Larkin, Robert D. Pelletier, Jeannine M. Chan, Jeevan B. GC, Senthil Natesan & John P. Harrelson. (2020) Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde. Drug Metabolism and Disposition 48:10, pages 1028-1043.
Crossref
Crossref
Diego L. Lapetina, Esther H. Yang, Beatriz C. Henriques & Katherine J. Aitchison. 2020. Seminars in Clinical Psychopharmacology. Seminars in Clinical Psychopharmacology
151
202
.
Abdullah M. Alzahrani & Peramaiyan Rajendran. (2020) The Multifarious Link between Cytochrome P450s and Cancer. Oxidative Medicine and Cellular Longevity 2020, pages 1-18.
Crossref
Crossref
Murtala B. Abubakar, Huay Lin Tan, Venkata Murali Krishna Bhavaraju & Siew Hua Gan. (2019) Impact of CYP3A4 and CYP3A5 single nucleotide polymorphisms on anastrozole-associated adverse events among Malaysian breast cancer patients. Asia Pacific Journal of Molecular Biology and Biotechnology, pages 33-42.
Crossref
Crossref
Priyanka Arora, Courtney Huff Adams, Gary Gudelsky, Biplab DasGupta & Pankaj B. Desai. (2018) Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. Cancer Chemotherapy and Pharmacology 83:1, pages 81-89.
Crossref
Crossref
Mostafa Nasr, Mohamed Farghaly, Tarek Elsaba, Mohamed El-Mokhtar, Radwa Radwan, Mahmoud Elsabahy, Ahmed Abdelkareem, Hussein Fakhry & Noha Mousa. (2018) Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression. The International Journal of Biochemistry & Cell Biology 105, pages 84-93.
Crossref
Crossref
Adrienne E. Borrie, Rhiannon V. Rose, Yun-Hee Choi, Francisco E. Perera, Nancy Read, Tracy Sexton, Michael Lock, Theodore A. Vandenberg, Karin Hahn, Robert Dinniwell, Jawaid Younus, Diane Logan, Kylea Potvin, Brian Yaremko, Edward Yu, John Lenehan, Stephen Welch, Rachel F. Tyndale, Wendy A. Teft & Richard B. Kim. (2018) Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Research and Treatment 172:2, pages 371-379.
Crossref
Crossref
Malika P. Godamudunage, Anne M. Grech & Emily E. Scott. (2018) Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7. Drug Metabolism and Disposition 46:9, pages 1329-1337.
Crossref
Crossref
Xiaojing Ren, Yuanyuan Ji, Xuhua Jiang & Xun Qi. (2018) Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma. BioMed Research International 2018, pages 1-9.
Crossref
Crossref
Meghan J. Chenoweth, Jennifer J. Ware, Andy Z. X. Zhu, Christopher B. Cole, Lisa Sanderson Cox, Nikki Nollen, Jasjit S. Ahluwalia, Neal L. Benowitz, Robert A. Schnoll, Larry W. HawkJrJr, Paul M. Cinciripini, Tony P. George, Caryn Lerman, Joanne Knight & Rachel F. Tyndale. (2018) Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. Addiction 113:3, pages 509-523.
Crossref
Crossref
Julie-Anne Tanner & Rachel Tyndale. (2017) Variation in CYP2A6 Activity and Personalized Medicine. Journal of Personalized Medicine 7:4, pages 18.
Crossref
Crossref
Hiroyuki Kusuhara, Tadayuki Takashima, Hisako Fujii, Tsutomu Takashima, Masaaki Tanaka, Akira Ishii, Shusaku Tazawa, Kazuhiro Takahashi, Kayo Takahashi, Hidekichi Tokai, Tsuneo Yano, Makoto Kataoka, Akihiro Inano, Suguru Yoshida, Takamitsu Hosoya, Yuichi Sugiyama, Shinji Yamashita, Taisuke Hojo & Yasuyoshi Watanabe. (2017) Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects. Drug Metabolism and Pharmacokinetics 32:6, pages 293-300.
Crossref
Crossref
Alessandra Linardi, Durval Damiani & Carlos A. Longui. (2017) The use of aromatase inhibitors in boys with short stature: what to know before prescribing?. Archives of Endocrinology and Metabolism 61:4, pages 391-397.
Crossref
Crossref
Daniel L Hertz, N Lynn Henry & James M Rae. (2017) Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients. Pharmacogenomics 18:5, pages 481-499.
Crossref
Crossref
Ayorinde Adehin, Oluseye O. Bolaji, Simran Maggo & Martin A. Kennedy. (2017) Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population. Drug Metabolism and Personalized Therapy 32:1, pages 39-47.
Crossref
Crossref
Julie-Anne Tanner, Bhagwat Prasad, Katrina G. Claw, Patricia Stapleton, Amarjit Chaudhry, Erin G. Schuetz, Kenneth E. Thummel & Rachel F. Tyndale. (2017) Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. Journal of Pharmacology and Experimental Therapeutics 360:1, pages 129-139.
Crossref
Crossref
J. Chan, T. Oshiro, S. Thomas, A. Higa, S. Black, A. Todorovic, F. Elbarbry & J. P. Harrelson. (2016) Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. Drug Metabolism and Disposition 44:4, pages 534-543.
Crossref
Crossref
Souzan B. Yanni. 2015. Translational ADMET for Drug Therapy. Translational ADMET for Drug Therapy
277
306
.
Mark Piliguian, Andy Z.X. Zhu, Qian Zhou, Neal L. Benowitz, Jasjit S. Ahluwalia, Lisa Sanderson Cox & Rachel F. Tyndale. (2014) Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. Pharmacogenetics and Genomics 24:2, pages 118-128.
Crossref
Crossref
Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab & Thomas E. Mürdter. (2013) The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. Drug Metabolism and Disposition 41:11, pages 1906-1913.
Crossref
Crossref
Qin Wang. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
3
.
Danny W. K. Lum, Pablo Perel, Aroon D. Hingorani & Michael V. Holmes. (2013) CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE 8:10, pages e76648.
Crossref
Crossref
Ulrich M. Zanger & Matthias Schwab. (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 138:1, pages 103-141.
Crossref
Crossref
Hiromi Tanii, Yoshihisa Shitara, Mikako Torii, Shuichi Sekine, Hiroshi Iwata & Toshiharu Horie. (2013) Induction of Cytochrome P450 2A6 by Bilirubin in Human Hepatocytes. Pharmacology & Pharmacy 04:02, pages 182-190.
Crossref
Crossref
Ellen M. McDonagh, Catherine Wassenaar, Sean P. David, Rachel F. Tyndale, Russ B. Altman, Michelle Whirl-Carrillo & Teri E. Klein. (2012) PharmGKB summary. Pharmacogenetics and Genomics 22:9, pages 695-708.
Crossref
Crossref
Matthias Schwab, Elke Schaeffeler & Hiltrud Brauch. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
365
378
.
Kristen D Hadfield & William G Newman. (2012) Pharmacogenetics of aromatase inhibitors. Pharmacogenomics 13:6, pages 699-707.
Crossref
Crossref
Jana C. Precht, Boian Ganchev, Georg Heinkele, Hiltrud Brauch, Matthias Schwab & Thomas E. Mürdter. (2012) Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS. Analytical and Bioanalytical Chemistry 403:1, pages 301-308.
Crossref
Crossref
Alexander V. LyubimovHiroshi Yamazaki. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
13
.
Z Desta, Y Kreutz, A T Nguyen, L Li, T Skaar, L K Kamdem, N L Henry, D F Hayes, A M Storniolo, V Stearns, E Hoffmann, R F Tyndale & D A Flockhart. (2011) Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age. Clinical Pharmacology & Therapeutics 90:5, pages 693-700.
Crossref
Crossref
Hiromi Tanii, Yoshihisa Shitara & Toshiharu Horie. (2011) Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. European Journal of Clinical Pharmacology 67:10, pages 1017-1025.
Crossref
Crossref